Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.
about
Landmark trials affecting the surgical management of invasive breast cancerRecent progress in the treatment and prevention of cancer-related lymphedemaMapping lymph nodes in cancer management - role of (99m)Tc-tilmanocept injectionSentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis.Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review.Complication rates in patients with negative axillary nodes 10 years after local breast radiotherapy after either sentinel lymph node dissection or axillary clearance.Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).A simple model to assess the probability of invasion in ductal carcinoma in situ of the breast diagnosed by needle biopsy.Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32.Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32.Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialSentinel node biopsy for breast cancer patients: issues for discussion and our practice.ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trialAxillary recurrences following positive sentinel lymph node biopsy with individual tumor cells or micrometastases and no axillary dissection.Axillary reverse mapping: five-year experience.The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review.Diagnostic accuracy of sentinel node identification is maintained with the addition of local lidocaine and subareolar radioactive colloid injection.Review of breast conservation therapy: then and nowSentinel Lymph Node Detection Using Carbon Nanoparticles in Patients with Early Breast CancerThe clinical manifestations and treatment of male breast cancer: a report of three cases.Contrast-Enhanced Color Doppler Ultrasonography for Preoperative Evaluation of Sentinel Lymph Node in Breast Cancer Patients.A nomogram to predict the probability of axillary lymph node metastasis in early breast cancer patients with positive axillary ultrasound.Comparison of relative versus absolute arm size change as criteria for quantifying breast cancer-related lymphedema: the flaws in current studies and need for universal methodology.A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearanceScreening for breast cancer-related lymphedema: the need for standardizationAxillary radiotherapy: an alternative treatment option for adjuvant axillary management of breast cancer.Lymphedema following treatment for breast cancer: a new approach to an old problem.Long-term effects of complex decongestive therapy in breast cancer patients with arm lymphedema after axillary dissection.Sparing sentinel node biopsy through axillary lymph node fine needle aspiration in primary breast cancers.Breast and gynecologic cancer-related extremity lymphedema: a review of diagnostic modalities and management options.Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients.Sentinel lymph node biopsy in primary breast cancer: window to management of the axilla.Breast-cancer related lymphedema: a review of procedure-specific incidence rates, clinical assessment AIDS, treatment paradigms, and risk reduction.Accelerated partial breast irradiation for early-stage breast cancer: controversies and current indications for use.Is DCIS breast cancer, and how do I treat it?Blue dye is sufficient for sentinel lymph node biopsy in breast cancer.Shoulder and arm morbidity in sentinel node-negative breast cancer patients: a systematic review.Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ.
P2860
Q26830129-E4C3C75E-4D36-47B0-B905-97DEBB80BB80Q27009895-73866996-DA8F-472A-A49B-DEFB8BFC9754Q27022042-6DE8D562-5699-4BBE-99C0-000589B5C51EQ31022615-72A7C330-CC4E-4150-B31D-FC584D20814EQ33590486-B165D1F4-9B05-499F-A17E-FF3177182D49Q33783188-C76FAB5D-9176-40CC-9737-3D706889990BQ33862578-4ED6053C-826C-4F42-9A00-F60A0717FB87Q33992894-ED207059-3AEB-482E-8A99-988D6A0949E1Q34039923-26084BB2-2FC3-485C-AA5C-F9E6C81D6975Q34131757-5566463E-E9A3-4B51-A6E1-14298428F434Q34139672-29BCC5EB-2E57-4B0D-A175-A1B66A7B18E6Q34479099-523EB9F1-E00D-4DB2-B04E-3C33D6F11B56Q34680978-ABE9550E-3D1F-4B25-99E2-00EFB6819C0EQ34919537-05796AA9-8E58-4A3D-A35C-F91048BD1293Q35125432-5E2B8B80-14BB-4D5E-8A0E-5311D8B6CDB1Q35163199-CDF98399-E4FB-4054-BCEA-BDAAD36BB87EQ35225111-64D92EE0-C0C7-4D4D-8FDC-9EBF6EE515ADQ35300133-C3225AE8-BA1B-4A5B-ACD9-10EE2BBB2883Q35433289-E1E6F426-DD4C-43A3-A32D-116E93321D03Q35752488-14FDDBA0-ACE4-4690-99DB-52AD1AD84B85Q36123350-9F10BCD4-1368-4B22-9897-A2B40F66478BQ36368153-086B2AA6-01A1-4423-BBBC-DAAF3615BCA5Q36579394-FCC7996C-0904-4ACF-A5D9-41ECB5E7938DQ36587170-B1FE67EA-9AD0-4B34-8A3D-5C5623551904Q36757710-BDB79F3A-9E09-4732-8EF2-8C3B6DDB38E8Q36804470-DC936C57-3ADF-4B51-9164-B03308037197Q36925117-B211272E-8107-49BD-B32D-8368ED7AC461Q37200954-2455A09E-9D4B-49BC-98BF-34ADB9580052Q37303487-C754919A-1479-4939-A265-4F87B47202ADQ37348043-C08982BD-BCBA-4689-A196-A3F5B071855CQ37366477-F8877103-2B29-453D-A862-F9383D25B140Q37417172-EE7FA242-AA7D-48DC-A646-570D29178BC1Q37702991-4EA7574A-A175-4336-A93F-DF0CA000358CQ38007324-A52820F8-3043-4188-9CE1-ADF7C152862AQ38023590-84825FEC-CF83-4961-94BD-21232CF2AE6BQ38062411-5D0E307E-25B6-4776-9580-54AEAC64C521Q38067318-711C13A8-6149-4230-A91F-C304745EDAC3Q38184924-9B6EC2D7-5413-48E5-B9A3-137E1DFBC087Q38185305-86A6DE44-5666-4856-B2B2-E6B6A4F77A71Q38393043-9CAC79A4-66B8-422B-BF75-E37089C81B39
P2860
Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Morbidity results from the NSA ...... on versus axillary dissection.
@ast
Morbidity results from the NSA ...... on versus axillary dissection.
@en
Morbidity results from the NSA ...... on versus axillary dissection.
@nl
type
label
Morbidity results from the NSA ...... on versus axillary dissection.
@ast
Morbidity results from the NSA ...... on versus axillary dissection.
@en
Morbidity results from the NSA ...... on versus axillary dissection.
@nl
prefLabel
Morbidity results from the NSA ...... on versus axillary dissection.
@ast
Morbidity results from the NSA ...... on versus axillary dissection.
@en
Morbidity results from the NSA ...... on versus axillary dissection.
@nl
P2093
P2860
P356
P1476
Morbidity results from the NSA ...... ion versus axillary dissection
@en
P2093
Ann M Brown
David N Krag
Donald L Weaver
Eleftherios P Mamounas
Joan M Skelly
Joseph P Costantino
National Surgical Adjuvant Breast, Bowel Project
Norman Wolmark
Seth P Harlow
Stephanie R Land
P2860
P304
P356
10.1002/JSO.21535
P577
2010-08-01T00:00:00Z